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Background: Alzheimer’s Disease (AD) is a progressive neurodegenerative disease, especially affecting the
hippocampus. Impairment of cognitive and memory functions is associated with amyloid β-peptide-induced
oxidative stress and alterations in lipid metabolism. In this scenario, the dual role of peroxisomes in producing and
removing ROS, and their function in fatty acids β-oxidation, may be critical. This work aims to investigating the
possible involvement of peroxisomes in AD onset and progression, as studied in a transgenic mouse model,
harboring the human Swedish familial AD mutation. We therefore characterized the peroxisomal population in the
hippocampus, focusing on early, advanced, and late stages of the disease (3, 6, 9, 12, 18 months of age). Several
peroxisome-related markers in transgenic and wild-type hippocampal formation were comparatively studied, by a
combined molecular/immunohistochemical/ultrastructural approach.
Results: Our results demonstrate early and significant peroxisomal modifications in AD mice, compared to wild-
type. Indeed, the peroxisomal membrane protein of 70 kDa and acyl-CoA oxidase 1 are induced at 3 months,
possibly reflecting the need for efficient fatty acid β-oxidation, as a compensatory response to mitochondrial
dysfunction. The concomitant presence of oxidative damage markers and the altered expression of antioxidant
enzymes argue for early oxidative stress in AD. During physiological and pathological brain aging, important
changes in the expression of peroxisome-related proteins, also correlating with ongoing gliosis, occur in the
hippocampus. These age- and genotype-based alterations, strongly dependent on the specific marker considered,
indicate metabolic and/or numerical remodeling of peroxisomal population.
Conclusions: Overall, our data support functional and biogenetic relationships linking peroxisomes to mitochondria
and suggest peroxisomal proteins as biomarkers/therapeutic targets in pre-symptomatic AD.
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Alzheimer’s disease (AD) is the most common form of
dementia, characterized by progressive neurodegenera-
tion, particularly affecting the hippocampal formation.
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reproduction in any medium, provided the orincreased oxidative stress, lipid metabolism alteration,
and inflammation [1-5].
The central role of peroxisomes in reactive oxygen
species (ROS) metabolism has emerged since their dis-
covery [6]. In fact, peroxisomes participate in both ROS
generation and removal, under physiological or patho-
logical conditions. Moreover, peroxisomes are involved
in a wide range of catabolic and anabolic functions, in-
cluding β-oxidation of very long chain fatty acids
(VLCFAs) [7,8], biosynthesis of polyunsaturated fatty
acids and plasmalogens [9,10], and calcium homeostasisLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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somes can also function as intracellular signaling com-
partments and organizing platforms that orchestrate
important developmental decisions from inside the cell
[13]. These dynamic and versatile organelles respond to
physiological and pathological changes in cellular envir-
onment by adapting their morphology, number and en-
zyme content accordingly [14]. Peroxisomal dysfunction
has been shown to be associated with cellular aging as
well as with age-related degenerative diseases [13]. The
potential role of peroxisomes in human AD, especially in
relationship with lipid metabolism, has recently been
suggested [15]. Indeed, a decrease in plasmalogens and,
conversely, an increase in VLCFAs, were described in
cases with advanced Braak stages [16]. Moreover, in an
in vitro model of advanced AD a decrease of peroxi-
somes in hippocampal neurons was reported, while
induction of peroxisomal proliferation attenuated Aβ-
dependent toxicity [17]. We previously demonstrated
that peroxisomes are involved in early stages of AD, as
studied either in vivo, in a transgenic mouse model [18],
or in vitro, on Aβ treated cortical neurons [19].
The aim of the present work was to investigate the
role of peroxisomes during the progression of AD and in
normal aging. To this purpose, we utilized the Tg2576
(Tg) mouse model, compared to its wild-type (WT)
counterpart. Differently from other mouse models, this
strain displays a slowly progressive AD pathology, offer-
ing the opportunity to study even subtle age-dependent
alterations [20-23]. By combined molecular and mor-
phological approaches, we examined the expression of
peroxisome-related proteins in the hippocampal forma-
tion at early and advanced AD stages (3, 6, 9, 12, and
18 months). We focused on the CA1 hippocampal re-
gion, as pyramidal cells in this field are the most
profoundly affected cell type in human AD [24]. Specif-
ically, the expression and immunolocalization patterns
of peroxisomal membrane protein of 70 kDa (PMP70),
peroxin 14p (Pex14p), catalase (CAT), acyl-CoA oxidase
1 (AOX), and 3-ketoacyl-CoA thiolase (THL) were stud-
ied, to get an insight into the biogenesis and functioning
of peroxisomes in the diseased brain. Given the involve-
ment of peroxisomes in the maintenance of the redox
status, antioxidant enzymes other than CAT, namely
selenium-dependent glutathione peroxidase (GPX1),
Cu,Zn-superoxide dismutase (SOD1), and Mn-superoxide
dismutase (SOD2) were also investigated in Tg ani-
mals and in their WT littermates. It is worth recalling
that these proteins, though mainly localized to differ-
ent cell compartments, were also found in peroxi-
somes [25]. At selected stages, markers for oxidative
damage to lipids and nucleic acids - acrolein and
8-hydroxy(deoxy)guanosine (8-OH(d)G), respectively -
were also studied.Notably, the size and functions of peroxisomal po-
pulation are regulated by a class of ligand-activated
transcription factors (peroxisome proliferator-activated
receptors, PPARs) [26]. Among these, we studied PPARα
which is directly involved in peroxisomal induction [27],
plays a neuroprotective role in age-related inflammation
[28] and enhances memory consolidation [29]. It is
worth-mentioning in this context that PPARα specific
agonists have been demonstrated to exert a neuropro-
tective action against Aβ-mediated toxicity in vitro
[17]. Finally, we examined the expression of PPARγ
coactivator-1γ (PGC-1α), in view of its synergism with
PPARα and its implication in peroxisomal remodeling
and biogenesis [30,31].
Results
The distribution of peroxisomes in Tg and WT hippo-
campal formation from 3-, 6-, 9-, 12-, and 18-month-old
mice was investigated by analyzing the expression of
peroxisomal membrane (PMP70, Pex14p) and matrix
(CAT, AOX, THL) proteins. Markers of oxidative dam-
age to nucleic acids (8-OH(d)G) and to lipids (acrolein),
as well as antioxidant enzymes (SOD1, SOD2, GPX1),
were also studied. Further, to get an insight into the
transcriptional regulation of these genes, PPARα and
PGC-1α expression was examined. At selected stages,
the presence of PMP70 and PPARα in neuronal and/or
astroglial cells was studied by immunofluorescence and
their ultrastructural localization was investigated by
immunoelectron microscopy.
Peroxisomal membrane proteins: Pex14p and PMP70
Pex14p is a membrane-anchored peroxin, involved in
the peroxisomal import of matrix proteins [32-34], and
thus considered a dependable marker for peroxisomal
number [35]. Pex14p hippocampal levels, as assessed by
densitometric analysis of WB (Figure 1a), show no
genotype-dependent differences throughout the exam-
ined period, except for 18 months of age, when remark-
ably higher protein concentration in Tg, compared to
WT, is detected. Rather, age-related decreases are
observed in both normal and diseased animals, namely
between 3 and 6 months in the former, and between 6
and 9 months in the latter. This pattern is consistent
with Pex14p immunohistochemical staining of pyramidal
neurons in CA1 hippocampal field (Figure 1b).
PMP70, a major component of mammalian peroxisomal
membranes, is also considered as a good marker for the
overall size of peroxisomal population [36]. This ATP-
binding cassette transporter, also known as ABCD3, is sug-
gested to be responsible for the metabolic transport of long
and branched-chain fatty acyl-CoAs [37]. Our WB data
(Figure 2a) show a significant PMP70 induction in 3-month-
old Tg hippocampus compared to control. A decrease at
Figure 1 Pex14p protein levels and distribution in the hippocampus of WT and Tg mice. (a) Densitometric values of Pex14p WB,
performed on hippocampal protein extracts of 3-, 6-, 9-, 12-, and 18-month-old WT and Tg mice. Data are expressed as mean ± SD. *P <0.05; **P
<0.01; ***P <0.001. (b) Pex14p immunohistochemical localization in CA1 hippocampal field of 3-, 6-, 9-, and 18-month-old WT and Tg mice. or,
stratum oriens; pyr, stratum pyramidale; rad, stratum radiatum. Scale bars, 25 μm.
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dramatic in the diseased mice. Neither age- nor genotype-
related variations are detected at 9 and 12 months, while a
peak of PMP70 protein levels is observed at 18 months, par-
ticularly in the pathological genotype.
PMP70 immunohistochemical results on the CA1 hip-
pocampal field are in agreement with molecular data
(Figure 2b). Indeed, 3-month-old Tg pyramidal cell layer
displays stronger immunoreactivity than its WT counter-
part, while, at 6 months, decreased immunostaining is
observed in both genotypes. At 9–12 months of age,
immunostaining levels remain stable, and they remarkably
increase in 18-month-old hippocampus, especially in thesomata of Tg pyramidal neurons. PMP70 pre-embedding
immunoelectron microscopy allowed us to identify posi-
tive peroxisomes in 3-month-old CA1 pyramidal neurons,
in both WTand Tg animals (Figure 2c). The immunoreac-
tion product appears confined to the membrane, as
expected. Consistent with molecular and immunohisto-
chemical data, ultrastructural analysis shows numerous
PMP70 immunoreactive peroxisomes in hippocampal cells
of young Tg mice.
The strong PMP70 immunoreactivity observed at
18 months suggests possible contribution by astroglio-
sis to peroxisome numerical increase. To address this
issue, we performed GFAP immunohistochemistry and
Figure 2 PMP70 protein levels and distribution in the hippocampus of WT and Tg mice. (a) Densitometric values of PMP70 WB, obtained
analyzing the hippocampal protein extracts of 3-, 6-, 9-, 12-, and 18-month-old WT and Tg mice. Data are expressed as mean ± SD. *P <0.05; **P
<0.01; ***P <0.001. (b) Immunohistochemical distribution of PMP70 in CA1 hippocampal field of 3-, 6-, 9-, and 18-month-old WT and Tg mice. or,
stratum oriens; pyr, stratum pyramidale; rad, stratum radiatum. Scale bars, 25 μm. (c) PMP70 pre-embedding immunoelectron microscopy of 3-
month-old CA1 pyramidal neurons of WT and Tg animals. In both genotypes positive peroxisomes (arrows) are observed and they appear more
numerous in the cytoplasm of Tg neurons. N, neuronal nucleus; m, mitochondrion. Scale bars, 1 μm.
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immunofluorescence of PMP70 in combination with
GFAP (Figure 3c). As expected, astrogliosis is present
in the aging hippocampus, particularly in the Tg ani-
mals, and also associates with senile plaques. Confocal
images of 18-month-old WT and Tg CA1 fields show
bright PMP70 immunofluorescence in GFAP– and
GFAP+ cells, in both genotypes. PMP70+/GFAP+ cells
are especially numerous in Tg, demonstrating that per-
oxisomal increase in the AD senescent hippocampus is
importantly contributed by astroglial cells.Peroxisomal fatty acid β-oxidation enzymes
Even though the important role of peroxisomal β-
oxidation in brain development and functioning is well
recognized [8], no information on this metabolic path-
way in AD is presently available. We therefore analyzed
the expression of two major peroxisomal β-oxidation
enzymes, namely AOX and THL at the onset and during
the progression of AD. The former is the rate-limiting
enzyme catalyzing the first step of the cycle, while THL
is the last enzyme of the pathway. In 3-month-old Tg
hippocampus, AOX expression is significantly higher
Figure 3 GFAP protein levels and distribution in the hippocampus of WT and Tg mice. (a) GFAP immunohistochemical localization in CA1
hippocampal field of 9-, 12-, and 18-month-old WT and Tg mice. or, stratum oriens; pyr, stratum pyramidale; rad, stratum radiatum. Scale bars,
25 μm. (b) Densitometric analysis of GFAP WB performed on hippocampal protein extracts of 3-, 6-, 9-, 12-, and 18-month-old mice. Values are
expressed as mean ± SD. **P < 0.01; ***P < 0.001. (c) Double immunofluorescence of PMP70 (green) in combination with GFAP (red) in the CA1
hippocampal field of 18-month-old WT and Tg brain. Several PMP70+/GFAP+ cells (yellow) are especially numerous in the pathological genotype.
Scale bars, 25 μm.
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6 months, protein levels significantly decrease and remain
relatively low throughout the progression of disease. This
pattern is supported by AOX immunohistochemical ana-
lysis, showing intense immunoreactivity in CA1 pyramidal
cell somata of 3-month-old Tg hippocampus, not observed
at subsequent stages (Figure 4b). The expression pattern of
THL displays no genotype- or age-linked variations, except
for 18 months, when hippocampal levels are strongly
decreased in both genotypes, suggesting age-dependent
impairment of peroxisomal β-oxidation (Figure 4c).ROS-scavenging enzymes: CAT, GPX1, SOD1 and SOD2
Peroxisomes play a pivotal role in the protection against
ROS, mainly through their CAT activity, but also thanks
to their content in SOD1, SOD2, and GPX1 [25,38,39].
High CAT levels are found in 3-month-old hippocampus
irrespective of the genotype, while at 6 months signifi-
cantly higher values are observed in Tg, as compared to
WT (Figure 5a). At 9 months, CAT expression in the Tg
decreases to WT levels, which are maintained at later
ages in both genotypes. These data are confirmed by
immunohistochemical results, CA1 pyramidal neurons
Figure 4 Peroxisomal fatty acid β-oxidation enzymes in the hippocampus of WT and Tg mice. (a, c) Densitometric values of AOX and THL
WB performed on hippocampal protein extracts of 3-, 6-, 9-, 12-, and 18-month-old WT and Tg brains. Data are expressed as mean ± SD. *P <0.05;
**P <0.01; ***P <0.001. (b) AOX immunolocalization in CA1 hippocampal field of 3-, 6-, and 18-month-old WT and Tg brains. or, stratum oriens; pyr,
stratum pyramidale; rad, stratum radiatum. Scale bars, 25 μm.
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campus (Figure 5b).
The other major H2O2–scavenging enzyme, GPX1,
shows no significant variations during normal aging,
while differences in its expression levels are seen in
the pathological genotype, during AD progression. In-
deed, at 3 months, GPX1 expression in Tg is lower
than in WT, increasing thereafter, to reach signifi-
cantly higher levels than WT at 9 months. In the aging
Tg hippocampus a progressive decrease in GPX1 pro-
tein, below WT levels, is observed (Figure 5c). Immu-
nohistochemical data are consistent with WB data
(Figure 5d).The molecular and morphological expression patterns
of the two enzymes responsible for the dismutation of
the superoxide anion to hydrogen peroxide – SOD1 and
SOD2 – are shown in Figures 6 and 7, respectively. As
to SOD1 (Figure 6a, b), in 3-month-old Tg hippocampus
its levels are significantly lower than in WT, but progres-
sively increase thereafter, reaching at 9 months signifi-
cantly higher levels than its WT counterpart. SOD1
expression remains stable in the Tg at 12 months of age,
when WT levels are instead maximally increased, and
sharply decreases at 18 months in both genotypes.
SOD2 expression pattern during normal aging
(Figure 7a, b) closely resembles that of SOD1 in WT
Figure 5 H2O2-scavenging enzymes in WT and Tg hippocampus. (a, c) Densitometric values of CAT and GPX1 WB performed on
hippocampal protein extracts of 3-, 6-, 9-, 12-, and 18-month-old WT and Tg brains. Values are expressed as mean ± SD. *P <0.05; **P <0.01; ***P
<0.001. (b, d) CAT and GPX1 immunolocalization in CA1 hippocampal field of 3-, 6-, 9- and 18-month-old WT and Tg brains. or, stratum oriens; pyr,
stratum pyramidale; rad, stratum radiatum. Scale bars, 25 μm.
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tions are observed. Interestingly, SOD2 levels are sig-
nificantly higher in 3- and in 18-month-old Tg
hippocampus, compared to their WT counterparts.
Remarkably, at 18 months, SOD2 mainly localizes to
glial cells surrounding senile plaques in Tg hippocampus
(Figure 7c).
Oxidative stress markers: acrolein and 8-OH(d)G
To evaluate possible oxidative stress occurring in the
hippocampus during normal and pathological aging,
markers of oxidative damage to biomolecules were
investigated by immunohistochemistry. Antibodies to
acrolein, marker of lipid peroxidation (Figure 8a), and to
8-OH(d)G, marker of DNA/RNA oxidative modifications
(Figure 8b), were tested at 3 and 18 months, as represen-
tative of early and advanced AD stages.
We found a similar immunoreactivity pattern for both
markers, strongly related to the genotype, in that intense
labeling in Tg CA1 pyramidal layer was observed, as
early as 3 months, when WT neurons are faintly immu-
nopositive in their cytoplasm. In 18-month-old hippo-
campus, oxidative damage markers are detected in both
WT and Tg CA1 pyramidal cells, even though the
former are consistently less immunoreactive than the
latter. Intriguingly, the intensity of 8-OH(d)G immunor-
eaction at 18 months in Tg CA1 neurons appears lower
than at 3 months, suggesting a lower degree of oxidative
damage to nucleic acids in late AD.
PPARα and PGC-1α
Since the expression and activity of PPARα, major regu-
lator of peroxisome biogenesis, is influenced by oxidative
stress [28], we also addressed the putative involvement
of this transcription factor at the onset and at late stages
of AD. PPARα immunostaining of CA1 pyramidal cell
layer shows significantly higher levels in 3-month-old
Tg hippocampus, compared to its WT counterpart
(Figure 9a). Triple immunofluorescence experiments of
PPARα in combination with the neuronal marker NeuN
and the astroglial marker GFAP, confirm high expression
of the receptor in 3-month-old Tg neuronal cell nuclei
and demonstrate its presence also in glial cell nuclei
(Figure 9b). Pre-embedding immunoelectron microscopy
further confirms the massive presence of PPARα within
the nucleus of Tg hippocampal pyramidal neurons
(Figure 9c).
Given the growing evidence for a PGC-1α-mediated
transcriptional regulation in response to oxidative stress
and in view of its roles in peroxisome biogenesis [31]
and in promoting the nonamyloidogenic pathway of
APP [40], we analyzed the immunohistochemical
localization of this coactivator in the hippocampal CA1region (Figure 10). At 3 months of age, PGC-1α appears
localized in both the nucleus and the cytoplasm, includ-
ing dendrites extending in the stratum radiatum, of WT
and Tg hippocampus. Interestingly, at 6 months, immu-
noreactivity is highly concentrated in Tg neuronal nuclei,
while in WT hippocampus nuclear localization is
observed at 9 months. At the latest age considered, a
general decrease in immunoreactivity is detected.Discussion
The aim of the present study was to investigate the role
of peroxisomes in AD onset and progression. In a previ-
ous work [18], peroxisomal involvement in early AD was
demonstrated in the Tg2576 mouse model, also used in
this work. Differently from that study, in which male
animals were analyzed, we here utilized females, since
epidemiological and histopathological data indicate this
as the most AD-affected gender in mice and humans
[41,42]. We focused on the hippocampal formation, i.e.,
the primarily affected area of the diseased brain [43].
The expression of peroxisome-related proteins was
studied by combined molecular and morphological
approaches, at the onset (3 months) and during AD pro-
gression (6, 9, 12, 18 months) in Tg animals, compared
to their WT counterparts.
Our results demonstrate that significant peroxisomal
alterations occur in Tg mice, as early as 3 months. These
early changes are consistent with behavioral, electro-
physiological, ultrastructural and molecular modifications
reported in this model at the same age [22]. Indeed,
PMP70, long been considered marker of the numerical
size of peroxisomal population [36] is upregulated, as
assessed by WB. Consistently, PMP70 immunohistochem-
istry reveals especially intense immunostaining in the pyr-
amidal layer of Tg hippocampal CA1 subdivision, and
immunoelectron microscopy shows numerous positive
peroxisomes in the somata of these neurons.
Differently from PMP70, the biogenesis marker
Pex14p, also used to evaluate peroxisome number [35],
is unchanged in 3-month-old Tg animals. The absence
of correlation between PMP70 and Pex14p levels in early
AD could either indicate specific concentration of
PMP70 in a numerically unchanged peroxisomal popula-
tion, or impoverishment of Pex14p in proliferated per-
oxisomes. In either case, the altered content in these
proteins likely results in profound modifications of per-
oxisomal functions. Interestingly, Pex14p has recently
been involved in microtubule-based peroxisome motility
[44], suggesting that at this early AD stage, peroxisomes,
endowed with a relatively low Pex14p/PMP70 ratio are
altered in their transport along neurites. To this respect,
it is worth mentioning that a recent work from Berger’s
group demonstrates an increased peroxisomal volume
Figure 6 SOD1 protein levels and distribution in WT and Tg hippocampus. (a) Densitometric values of SOD1 WB performed on
hippocampal protein extracts of 3-, 6-, 9-, 12- and 18-month-old WT and Tg brains. Values are expressed as mean ± SD. *P <0.05; **P <0.01; ***P
<0.001. (b) SOD1 immunolocalization in CA1 hippocampal field of 3-, 6-, 9-, 12- and 18-month-old WT and Tg brains. or, stratum oriens; pyr,
stratum pyramidale; rad, stratum radiatum. Scale bars, 25 μm.
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associated with impaired peroxisome trafficking [16].
The specific increase in early AD of PMP70, presum-
ably involved in fatty acyl-CoA import across peroxi-
somal membranes [37], could reflect the need for a
more efficient acyl-CoA β-oxidation. In agreement with
this hypothesis, AOX, rate-limiting enzyme of peroxi-
somal β-oxidation pathway, is upregulated in 3-month-
old Tg hippocampus. This increase could thus represent
a compensatory response to early Aβ-mediated mito-
chondrial insult, to cope with the impaired energy me-
tabolism, occurring in AD [45,46]. Indeed, abnormalities
in glucose metabolism/mitochondrial function are in-
variant features of early AD [46-49]. Consistently, posi-
tron emission tomography studies in AD patients report
abnormal cerebral glucose utilization, particularly in the
hippocampus, decades prior to the onset of histopatho-
logical and clinical features [50]. A consequent shift in
brain metabolism, from a primarily aerobic glycolysis
pathway to a ketogenic/fatty acid β-oxidation pathway is
thought to occur [51]. In this context, we suggest that
peroxisomal β-oxidation contributes to such metabolic
change, providing mitochondria with acetyl-CoA and
fatty acyl substrates. Induction of peroxisomal β-
oxidation pathway may also be neuroprotective, by en-
hancing the clearance of potentially toxic VLCFAs and
by promoting the biosynthesis of the neuroprotective
docosahexaenoic acid (DHA) [15]. Relevantly, elevated
levels of VLCFA have been found in human AD brain
lesions [16] and the ability of these fatty acids to trigger
oxidative stress and mitochondrial dysfunction on neural
cells has recently been demonstrated [52,53].
A biogenetic/metabolic relationship between peroxi-
somes and mitochondria has long been established and
recently emphasized [13,30,31]. In yeast, experimentally
induced or age-associated mitochondrial dysfunction
activates the so-called retrograde (RTG) signaling path-
way, leading to the transcription of RTG-target genes,
including those required for peroxisome biogenesis and
function [13]. Our results showing increased PPARα nu-
clear immunoreactivity allow us to speculate that this
gene be included among the above mentioned RTG-
target genes. The increased PPARα expression could in
turn be responsible for the induction of its target genes
PMP70 and AOX [54,55]. Even though the molecular
triggers of PPARα activation remain to be determined in
our model, endogenous production of PPARα ligands,
e.g., oxidized lipid molecules, is likely to occur due to
Aβ-mediated ROS generation.
While, in principle, AOX induction in 3-month-old Tg
hippocampus may represent a positive response to
enhanced need for lipid substrates to be processed in
mitochondria, this induction may also result in increased
H2O2 production by the oxidase. Moreover, mitochondrialrespiration supported by fatty acids generates substantial
rates of ROS production [56], thus contributing to cellular
redox status alteration. In this context, even the observed
early increase of SOD2 expression, in agreement with
reports demonstrating induction of mitochondrial genes
in young Tg mice [57], may contribute itself to redox im-
balance, through enhanced conversion of superoxide
anion to H2O2.
Notably, GPX1, the major cytosolic H2O2–scavenging
enzyme, is significantly down-regulated in our early AD
samples, further exacerbating imbalance between gener-
ation and removal of hydrogen peroxide. GPX1 seems
especially critical in AD, since its deletion increases
susceptibility of neurons to Aβ-mediated damage, while
its overexpression protects against neurodegeneration
[58,59]. The postulated pro-oxidant environment likely
results in post-translational modifications of GPX1 itself,
leading to its irreversible inactivation [60]. Even the low
levels of SOD1 detected in the young Tg hippocampus
may be explained taking into account that this cytosolic
protein is selectively damaged by H2O2 [61]. Importantly,
SOD1 deficiency in Tg2576 mice has been associated with
oxidative damage, accelerated Aβ oligomerization and
memory impairment [62].
Therefore, our data strongly support the idea that oxi-
dative stress is the primary culprit in AD pathogenesis
[63]. Consistently, 8-OH(d)G and acrolein, markers of
oxidative modification to biomolecules [64,65], show
DNA/RNA oxidation and lipoperoxidation in the hippo-
campus of young Tg mice. Interestingly, 8-OH(d)G
immunostaining is predominantly localized in the cyto-
plasm, suggesting that mitochondrial nucleic acids are
primarily affected. To our knowledge, this is the first
report of such a modification occurring at 3 months in
this mouse strain. In this context, it is worth mentioning
that acrolein has been suggested not only as a marker of
lipoperoxidation, but also as initiator of oxidative stress [65].
Between 3 and 6 months of age, most peroxisomal
markers decrease in WT hippocampal formation, indi-
cating a numerical reduction and/or a metabolic change
of the organelles in the physiological course of maturity.
By contrast, in Tg mice of the same age, when several
hallmarks of AD pathology make their appearance [21],
marker-specific patterns are observed. In particular,
while high levels of CAT and Pex14p are maintained,
PMP70 and AOX are significantly decreased, suggesting
metabolic, rather than numerical, modifications of per-
oxisomes. These changes, indicating decreased efficiency
of peroxisomal β-oxidation, presumably lead to VLCFA
accumulation, consistent with what reported in human
AD [16]. Interestingly, pharmacological inhibition of
peroxisomal β-oxidation, resulting in VLCFA accumula-
tion, is positively correlated with Aβ40 levels in rat cere-
bral cortex [66].
Figure 7 SOD2 protein levels and distribution in WT and Tg hippocampus. (a) Densitometric values of SOD2 WB performed on
hippocampal protein extracts of 3-, 6-, 9-, 12- and 18-month-old WT and Tg brains. Values are expressed as mean ± SD. **P <0.01; ***P <0.001.
(b) SOD2 immunolocalization in CA1 hippocampal field of 3-, 6-, 9-, 12- and 18-month-old WT and Tg brains. or, stratum oriens; pyr, stratum
pyramidale; rad, stratum radiatum. Scale bars, 25 μm. (c) Higher magnification showing SOD2 immunopositive glial cells around senile plaques in
18-month-old Tg hippocampus. Scale bar, 15 μm.
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Tg hippocampus are conceivably sustained by transcrip-
tion factors activated in response to oxidative stress. To
this respect, the cellular redox state sensor PGC-1α may
play a role in regulating CAT expression [67]. Our immu-
nohistochemical data support this relationship, in that at
6 months intense PGC-1α nuclear staining, suggestive of
its induction and activity, is observed in CA1 pyramidal
neurons, exclusively in Tg. The decrease in PGC-1α
nuclear immunostaining seen at later AD stages, also
parallels the behavior of CAT.
The same transcriptional co-activator, which has been
involved in aging and age-associated diseases [68], may
be responsible for the pattern of other antioxidant
enzymes. Indeed, the increased PGC-1α nuclear im
munoreactivity observed around 9–12 months in Wt
neurons is paralleled by the raise in SOD1 and SOD2
levels, occurring in 12-month-old normal hippocampus.
Conversely, the dramatically low expression of PGC-
1α at 12 months in AD neurons, when we first observe
hippocampal amyloid deposits (not shown), is
concomitant with the lower levels of SOD1, SOD2 and,
particularly, GPX1, compared to WT. Accordingly,
altered glutathione redox status has been associated to
the onset of amyloid plaques in a mouse model of ADFigure 8 Immunolocalization of oxidative stress markers at early and
hippocampal field of 3- and 18-month-old WT and Tg mice. or, stratum orie[69] and decreased activities of SOD1 and GPX1 have
been reported in symptomatic human AD [62,70]. By
contrast, SOD2 overexpression in Tg mice results in
diminished plaque formation [71].
In 18-month-old mouse hippocampus, genotype-
dependent variations are observed for most peroxisomal
and antioxidant proteins. At this stage, gliosis, known to
occur during brain aging and exacerbated in AD [72-74],
should be taken into account, when interpreting WB quan-
titative data. In fact, astrogliosis may be at least in part re-
sponsible for the peaks of PMP70 and Pex14p observed in
old Tg mice. An important contribution to the overall
brain peroxisomal population by astrocytes, highlighted by
our GFAP/PMP70 double immunofluorescence images, is
consistent with the notion that peroxisomes are abundant
in this cell type [75-77]. Nevertheless, our immunohisto-
chemical data on 18-month-old hippocampus clearly show
enhanced positivity to PMP70 and Pex14p also in CA1
pyramidal neurons, markedly in the Tg, suggesting a global
increase of peroxisome number in the hippocampal tissue,
contributed by both neuronal and glial cells. Differently
from the above membrane proteins, peroxisomal matrix
enzymes, namely CAT, AOX and THL are not increased
or even decreased, in 18-month-old hippocampus, possibly
owing to age-related low efficiency of peroxisomal proteinadvanced AD stages. (a, b) Acrolein and 8-OH(d)G in CA1
ns; pyr, stratum pyramidale; rad, stratum radiatum. Scale bars, 25 μm.
Figure 9 PPARα immunolocalization in 3-month-old WT and Tg mice. (a) PPARα immunohistochemistry in CA1 pyramidal cell layer shows a
higher immunoreactivity in Tg hippocampus, than in its WT counterpart. or, stratum oriens; pyr, stratum pyramidale; rad, stratum radiatum. Scale
bars, 25 μm. (b) Confocal image of triple immunofluorescence for PPARα (green) in combination with GFAP (red) and NeuN (blue) demonstrates
the presence of PPARα-positive neurons and astrocytes. Note the brightness of green signal in the Tg section. Scale bars, 25 μm. (c) PPARα pre-
embedding immunoelectron microscopy of CA1 pyramidal neurons shows the nuclear localization of the immunoreaction product, especially
concentrated in the Tg nucleus. Arrows indicate the nuclear envelope. N, nucleus; n, nucleolus. Scale bars, 2 μm.
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peroxisomal acyl-CoA β-oxidation in physiological and
pathological human aging [15,16].
Oxidative stress is known to occur in age-related neu-
rodegeneration [78,79]. Our results on 18-month-old
WT hippocampus show significantly lower levels of
SOD1 and SOD2 proteins, while GPX1 is not decreased,
with respect to previous ages. Thus, it seems that oxida-
tive damage in the aging hippocampus may result from
defective scavenging of superoxide anion, rather than
hydrogen peroxide. In 18-month-old Tg hippocampus,
GPX1 levels are significantly lower than in the corre-
sponding WT, indicating impaired removal of H2O2,
thus exacerbating the physiological age-related alteration
of the cellular redox status. Concerning SODs, while
SOD1 follows the decreasing trend of the age-matched
WT hippocampus, SOD2 is not decreased in 18-month
-old Tg, being significantly higher than in its WT coun-
terpart. This finding can be explained by immunohisto-
chemical data, showing particularly high concentration
of SOD2 in glial cells surrounding amyloid plaques.
Consistently, SOD2 - but not SOD1, CAT, or GPX1 - is
induced in astroglia by activated microglia in an in vitro
model of neuroinflammation [80].
A pro-oxidant cellular environment in the aged hippo-
campus is further demonstrated by the presence of
oxidative damage markers (acrolein and 8-OH(d)G), par-
ticularly concentrated in Tg neurons. However, while in
WT hippocampus both markers clearly show age-
dependent increase, the same is not true for the Tg,
where 8-OH(d)G immunoreactivity appears reduced in
18-month-old hippocampus, compared to the young.
This observation is in agreement with data from other
Authors indicating a negative correlation between 8-OH
(d)G levels and histological amyloid burden [81,82].
Conclusions
Overall, our results confirm and extend our previous
observations on the early involvement of peroxisomes in
AD pathogenesis [18]. In particular, we strongly suggest
that these organelles constitute a first line of defense in
support of mitochondria, primary targets of intracellular
Aβ/ROS-mediated damage. This protective role specific-
ally involves increased peroxisomal fatty acyl β-oxida-
tion, likely providing mitochondria with acetyl-CoA and
shortened acyl-CoAs. This conclusion may shed new
light into the physiological significance of peroxisome
metabolism in mature neurons, so far mainly related to
the synthesis of plasma membrane components and to
neurotransmission [7-10,83,84].
In brain aging, when oxidative stress sensu strictu
begins, peroxisomes become target of ROS, their func-
tions irreversibly decline, thus contributing themselves
to the “pro-oxidant loop” [13]. Deepening knowledge ofthese processes, which are associated to aging and accel-
erated/exacerbated in AD, will add significantly to the
dissection of pathogenic mechanisms of the disease. At
the same time, the early response shown by peroxisomes
supports the potential use of some of their proteins as
biomarkers, to recognize the first signs of presym-
ptomatic AD and to follow the effectiveness of novel
therapeutic approaches, possibly involving peroxisomal
induction. Indeed, preventing or treating the disease
earlier than in its mild to moderate stages presently
appears a major task, as stressed by the latest commen-
taries on the topic [85,86].Methods
Animals
Heterozygous female Tg mice [20] and WT littermates
were used for all experiments. Male mice (C57B6 × SJL),
hemizygous for human AβPP695 carrying the double
mutation K670N and M671L (FADSwedish mutation),
were purchased from Taconic Farms, Inc. (Germantown,
NY, USA). The Tg colony is maintained and the geno-
typing is performed as previously described [18].
For immunoblotting analyses, Tg and WT female mice
aging 3, 6, 9, 12, and 18 months were used. Six animals
from each group were killed by cervical dislocation,
brains were rapidly excised on an ice-cold plate, and the
hippocampus was dissected out before pooling samples
(three pools of two hippocampi each). For morphological
studies, three Tg mice and three WT littermates for each
age considered were deeply anesthetized with urethane
(1 g/kg body weight, injected i.p.), before rapid killing by
transcardial perfusion with the fixative solution.
Experiments were performed in accordance with the
European Community’s Council Directive 86/609/EEC.
Formal approval of these experiments was obtained from
the Italian Ministry of Health (D.L.vo 116/92; Prot. No.
155-VI-1.1.). All efforts were made to minimize the
number of animals used and their suffering.Molecular analyses
Total homogenate preparation from hippocampal tissue
Protein extraction was performed by homogenizing tis-
sue in lysis buffer (320 mM sucrose, 50 mM NaCl,
50 mM Tris–HCl, pH 7.5, 1% Triton X-100, 0.5 mM
sodium orthovanadate, 5 mM β-glycerophosphate, 1%
protease inhibitor), incubating on ice for 30 min. Homo-
genates were then centrifuged at 13,000 g for 10 min.
The total protein content of the resulting supernatant
was determined using a spectrophotometric assay,
according to Bradford [87]. Samples were then diluted
3:4 in 200 mM Tris–HCl, pH 6.8, containing 40% gly-
cerol, 20% β-mercaptoethanol, 4% sodium dodecyl phos-
phate (SDS), bromophenol blue.
Figure 10 PGC-1α immunohistochemistry in CA1 hippocampal field of 3, 6-, 9-, 12- and 18-month-old WT and Tg mice. Arrowheads, Aβ
plaques. or, stratum oriens; pyr, stratum pyramidale; rad, stratum radiatum. Scale bars, 25 μm.
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Western blotting (WB) experiments were performed as
previously described [18]. Membranes were probed at
4°C overnight with the following primary antibodies:
1:10000 rabbit polyclonal anti-Pex14p (generous gift of
Prof. R. Erdmann, Ruhr-Universität Bochum, Bochum,
Germany); 1:1000 rabbit polyclonal anti-PMP70 (Sigma-
Aldrich, St. Louis, MO, USA); 1:200 rabbit polyclonal
anti-glial fibrillary acidic protein (anti-GFAP, Sigma-
Aldrich); 1:1000 rabbit polyclonal anti-AOX (generous
gift of Prof. A. Völkl, University of Heidelberg, Heidel-
berg, Germany); 1:1000 rabbit polyclonal anti-THL (generous
gift of Prof. P. Van Veldhoven, Katholieke Universiteit
Leuven, Leuven, Belgium); 1:2000 rabbit polyclonal
anti-CAT (Rockland, Gilbertsville, PA, USA); 1:3000
rabbit polyclonal anti-GPX1 (Abnova, Taipei City, Tai-
wan); 1:1000 rabbit polyclonal anti-SOD1 (Abcam,
Cambridge Science Park, Cambridge, UK); 1:10000
anti-SOD2 (Abcam); 1:3000 mouse monoclonal anti-β
-actin (Sigma-Aldrich). This was followed by incuba-
tion with 1:2000 HRP-conjugated goat anti-rabbit or
anti-mouse IgG secondary antibodies (Santa Cruz Bio-
technology, Santa Cruz, CA, USA) in blocking solution,
for 1 h at 4°C. Immunoreactive bands were visualized
by a chemiluminescence detection kit (ECL Plus™
Western Blotting Detection Reagents, Amersham GE
Healthcare, Little Chalfont, UK). The relative densities
of immunoreactivity were determined by densitometry
using the software ImageJ (NIH, Bethesda, MD, USA)
and normalized with respect to β-actin. Data are mean
of five different experiments.Morphological analyses
Brain tissue preparation
Mice were perfusion-fixed and brains were paraffin-
embedded, as previously described [18]. The left halves
from 3-month-old Tg and WT brains were used for
immunoelectron microscopy.Immunohistochemistry
Serial, 5-μm-thick sagittal brain sections from Tg and WTani-
mals were deparaffinized and processed for immunohisto-
chemistry, as previously described [18]. The following primary
antibodies were used: 1:500 rabbit polyclonal anti-Pex14p
(generous gift of Prof. R. Erdmann); 1:200 rabbit polyclonal
anti-PMP70 (Sigma-Aldrich); 1:300 rabbit polyclonal anti-
GFAP (Dako, Glostrup, Denmark); 1:100 rabbit polyclonal
anti-AOX (generous gift of Prof. A. Volkl, Heidelberg); 1:200
rabbit polyclonal anti-CAT (Rockland); 1:100 rabbit polyclonal
anti-SOD1 and 1:1000 anti-SOD2 (Abcam); 1:500 rabbit poly-
clonal anti-acrolein (generous gift of Prof. K. Uchida, Nagoya
University, Nagoya, Japan); 1:200 rabbit polyclonal anti-
PPARα (ABR Affinity BioReagents, Golden, CO, USA); 1:50mouse monoclonal anti-PGC-1α (Calbiochem), and 1:500
mouse monoclonal anti-8OH(d)G (QED Bioscience Inc., San
Diego, CA, USA),. In control sections, the primary anti-
body was omitted. Biotinylated goat anti-rabbit IgG (Vec-
tor Laboratories, Burlingame, CA, USA), or biotinylated
goat anti-mouse IgG (Vector) were used as secondary
antibodies. Immuno-complexes were visualized, and slides
were dehydrated and mounted, as previously reported
[18]. Sections were observed under an Olympus BX 51
microscope, equipped with a Leica DFC 420 camera; elec-
tronic images were captured by a Leica Application Suite
system, and composed in an Adobe Photoshop CS5
format.
Immunofluorescence
For double immunofluorescence experiments, sagittal par-
affin sections from 18-month-old Tg and WT brains were
deparaffinized and rehydrated, as above. Sections were
incubated overnight at 4°C with a mixture of rabbit poly-
clonal anti-PMP70 (1:100, Sigma-Aldrich) and either mouse
monoclonal anti-GFAP (1:200, Chemicon, Temecula, CA,
USA), or mouse monoclonal anti-Neuronal Nuclei (anti-
NeuN 1:100, Chemicon). Sections were thoroughly rinsed
with PBS, then incubated for 1 h at RT with a mixture of
1:100 Alexa488 conjugated goat anti-rabbit IgG (Invitrogen)
and 1:500 Alexa555 conjugated goat anti-mouse IgG (Invi-
trogen). All antibodies were diluted with PBS containing
4% BSA. Triple immunofluorescence experiments were
performed on 3-month-old Tg and WT brains, using a
mixture of primary antibodies (1:100 rabbit polyclonal anti-
PPARα, 1:200 sheep polyclonal anti-GFAP, 1:100 mouse
monoclonal anti-NeuN) and of secondary antibodies (1:100
Alexa633 conjugated goat anti-rabbit IgG, 1:500 Alexa488
conjugated goat anti-mouse IgG, and 1:100 Alexa546 con-
jugated goat anti-sheep IgG). Controls were performed by
omitting the primary antibody. Slides were observed in a
Leica TCS SP5 confocal microscope and electronic images,
captured by a Leica Application Suite system, were com-
posed in an Adobe Photoshop CS5 format.
Immunoelectron microscopy
Samples from 3-month-old Tg and WT brains were sagittally
cut by a vibratome, and 100-μm-thick sections, were pro-
cessed for pre-embedding immunolocalization, according to
the previously described procedure [18]. Sections were incu-
bated with either 1:500 anti-PMP70 or with 1:150 anti-
PPARα, as primary antibodies, diluted in PBS. After immu-
nocomplexes visualization, slices were osmium-postfixed,
dehydrated, and flat-embedded in Epon as previously
described [18]. CA1 hippocampal fields of the resin-
embedded sections, identified in a light microscope, were
remounted on Epon blanks, and further sectioned on a
Reichert Ultracut S ultramicrotome. Ultrathin sections
were briefly contrasted with uranyl acetate and lead
Fanelli et al. Molecular Neurodegeneration 2013, 8:8 Page 17 of 19
http://www.molecularneurodegeneration.com/content/8/1/8citrate, and observed in a Philips CM120 electron micro-
scope equipped with a Philips Megaview III camera. Elec-
tronic images were captured by AnalySys 2.0 software and
composed in Adobe Photoshop CS5 format.
Statistical analysis
Statistical evaluation for WB experiments was performed
using GraphPad Prism 4 software. For comparison be-
tween genotypes and among different ages, statistical ana-
lysis of WB densitometric values was accomplished using
two-way analysis of variance (ANOVA) followed by the
Bonferroni test to detect significant differences between
groups. Means from independent experiments were then
expressed as means ± SD. For all statistical analyses,
P <0.05 was considered as statistically significant.
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